Image Analysis Group

Image Analysis Group (IAG) is a global leader in imaging clinical research, with nearly two decades of experience supporting biotech and pharmaceutical companies in optimizing and delivering clinical trials that rely on advanced medical imaging. Since 2007, IAG has successfully managed imaging for over 700 clinical trials across all phases (I-III), empowering sponsors to accelerate drug development and make confident, data-driven decisions.

Key Strengths and Experience:

Comprehensive Trial Support: IAG expertly manages all aspects of imaging in clinical trials, from study design and site setup to image acquisition, central review, and regulatory submission. Their experienced project managers ensure seamless execution and timely delivery, even in complex, multi-center global trials.

Proprietary Technology: IAG’s award-winning DYNAMIKA platform streamlines imaging data management, offering real-time quality control, advanced analytics, and AI-driven endpoints. This enables efficient data handling, accelerates patient recruitment, and provides sponsors with instant visibility into trial progress.

Therapeutic Breadth: IAG has deep expertise across a wide range of therapeutic areas, including oncology, immunology, rheumatology, neurology, rare diseases, obesity, and more. Their in-house radiology and medical experts ensure that imaging endpoints are tailored to the unique needs of each indication, maximizing the value of every trial.

AI-Powered Innovation: By integrating proprietary AI and machine learning tools, IAG delivers more sensitive and reproducible imaging endpoints, enabling earlier and more accurate assessments of drug efficacy and safety. This approach has been proven to reduce the number of patients needed and achieve statistically significant results faster, as demonstrated in published case studies.

Global Reach and Quality: With operational teams and partners across the UK, EU, USA, India, China, and Australia, IAG provides comprehensive support for international trials. Their rigorous quality management system is certified to the highest industry standards, ensuring data integrity and regulatory compliance at every step.

Proven Results:

IAG has a track record of helping sponsors achieve faster study outcomes, cleaner data for regulatory submissions, and reduced investment risk. Their collaborative approach and innovative solutions have delivered measurable value in high-profile partnerships and challenging therapeutic areas.

Why Choose IAG for Your Imaging Clinical Trials?

Partnering with Image Analysis Group means leveraging world-class expertise, state-of-the-art technology, and a commitment to operational excellence. Whether you are running early-phase exploratory studies or large-scale pivotal trials, IAG’s tailored solutions will maximize your trial’s success and accelerate your path to market.

Contact IAG today to discover how their imaging expertise can transform your clinical development program.

With nearly two decades of experience, a robust portfolio of successful partnerships, and a reputation for delivering high-quality, AI-powered imaging solutions, IAG is uniquely positioned to support biotech and pharma companies in achieving faster, more reliable clinical trial outcomes. Partnering with IAG means gaining a collaborative, expert-driven approach that de-risks clinical development and accelerates the path to market for novel therapies

Image Analysis Group (IAG) has been operating since 2007, giving the company over 17 years of experience as of 2025. Throughout this time, IAG has established itself as a trusted partner to biotech and pharmaceutical companies worldwide, specializing in the management of imaging for clinical trials across all phases (I-III) and a broad range of therapeutic areas.

Track Record Highlights:

Extensive Experience: IAG has supported hundreds of clinical trials, leveraging its award-winning DYNAMIKA platform and proprietary AI-driven methodologies to optimize trial design, accelerate data analysis, and ensure regulatory compliance.

Global Reach: The company operates internationally, with teams and partnerships spanning the UK, EU, USA, India, China, and Australia, enabling efficient support for global, multi-center trials.

Proven Results: IAG has a strong history of successful collaborations with leading biotech and pharma companies, providing critical imaging collection, centralized analysis, and expert assessment. Their expertise has been instrumental in advancing drug development programs, particularly in complex indications such as oncology, neurology, immunology, and rare diseases.

Innovation and Impact: By integrating advanced AI and quantitative imaging, IAG delivers more sensitive and reproducible endpoints, reducing patient numbers and timelines, and ultimately lowering investment risk for sponsors.

Industry Recognition: IAG’s commitment to innovation and operational excellence has been recognized through industry awards, including the 2024 Pharmaceutical Technology Excellence Award for its DYNAMIKA platform.

Therapeutic Areas and Indications of IAG Expertise
Image Analysis Group (IAG) offers deep expertise across a wide spectrum of therapeutic areas and indications, making it a preferred imaging partner for biotech and pharmaceutical companies seeking to optimize clinical trials with advanced imaging solutions.

Core Therapeutic Areas:

Oncology:
IAG has a significant focus on oncology, with nearly one-third of its clinical development experience dedicated to solid tumors, lymphomas, and brain tumors. The team is experienced in early and late-phase trials, including umbrella, adaptive, and basket trial designs, providing comprehensive imaging services and central review for cancer studies.

Immunology and Autoimmune Diseases:
IAG supports trials in immunology and autoimmune conditions, leveraging AI-powered imaging endpoints to enhance safety and efficacy assessments.

Neurology and CNS Disorders:
The group has substantial experience in neuroscience, including neuro-oncology, neurodegenerative diseases (such as Alzheimer’s), and CNS disorders. Advanced imaging techniques are used for precise volumetric and vascular assessments, enabling sensitive tracking of disease progression and therapeutic response.

Rheumatology and Musculoskeletal Disorders:
IAG is recognized for its expertise in rheumatology and musculoskeletal trials, including osteoarthritis, cartilage repair, and pain studies. The team uses MRI, CT, and X-ray to quantify structural changes and inflammation, supporting both efficacy and safety endpoints.

Obesity and Metabolic Disorders:
IAG’s proficiency with DXA and other imaging modalities enables precise measurement of lean mass, fat mass, and bone density—critical for obesity and metabolic disorder trials. The group has supported large-scale registrational studies and early-phase projects in obesity, sarcopenia, and related indications.

Bone Health and Osteoporosis:
IAG specializes in imaging for bone health, osteoporosis, and spinal fusion trials, using DXA, MRI, and X-ray to deliver robust safety and efficacy data. Their expertise includes patient stratification strategies that can reduce trial length and costs.

Rare Diseases:
The team has a proven track record in rare disease trials, designing imaging endpoints that address the unique challenges of these indications and supporting sponsors through all phases of development.

Additional Areas:
IAG also supports studies in respiratory, ophthalmology, radiopharmaceuticals, and other specialty indications, adapting imaging strategies to meet specific trial needs.

Case Studies and Client References
Image Analysis Group (IAG) has a strong track record of successful collaborations with leading biotech and pharmaceutical companies, demonstrated through a range of published case studies and client testimonials.

Selected Case Studies:

Ferring Pharmaceuticals – Women’s Reproductive Health:
IAG partnered with Ferring Pharmaceuticals to leverage AI-driven medical image analysis, advancing research in women’s reproductive health. This collaboration utilized IAG’s DYNAMIKA platform to efficiently handle large imaging datasets and uncover insights that traditional analysis might miss. Dr. Philippe Pinton, Senior Vice President at Ferring, highlighted the value of IAG’s AI-driven approach in unveiling hidden patterns and relationships within complex data.

Inflammatory Bowel Disease & Psoriatic Arthritis:
IAG has supported the development of breakthrough therapies for inflammatory bowel disease and psoriatic arthritis by applying advanced imaging analytics to better understand drug efficacy and support clinical decision-making.

Metastatic Melanoma and Immuno-Oncology:
IAG collaborated on the development of novel, targeted T-cell enhancing immuno-oncology therapeutics, applying AI-driven imaging strategies to support clinical trial programs in metastatic melanoma and other cancer indications.

Rare Disease – Turning Phase III Failure into Success:
In a notable case, IAG helped a global pharmaceutical company rescue a Phase III rare disease trial that initially failed to meet its endpoints. By re-analyzing imaging data with innovative methodologies, IAG addressed challenges related to data standardization and quality across nearly 250 global sites, ultimately enabling the sponsor to achieve statistically significant efficacy results faster.

Knee Osteoarthritis and Bone Health:
IAG’s AI-driven imaging analytics have been used to support clinical trial programs in knee osteoarthritis, providing sensitive endpoints and supporting both efficacy and safety assessments.

Industry Recognition:

IAG’s DYNAMIKA platform, central to many of these case studies, won the 2024 Pharmaceutical Technology Excellence Award for innovation, underscoring its impact on trial efficiency, data quality, and reproducibility.

Client Endorsements:

“The collaboration with IAG exemplifies our dedication to AI-driven research and development… harnessing AI to reveal deeper insights and bring the joy of delivering a healthy baby to women around the world.”
— Dr. Philippe Pinton, Senior Vice President, Ferring Pharmaceuticals

Image Analysis Group (IAG) has supported over 700 clinical trials since its founding in 2007, delivering imaging expertise and advanced technology solutions for biotech and pharmaceutical companies globally. This extensive track record spans all phases of clinical development and a wide range of therapeutic areas, demonstrating IAG’s proven ability to optimize imaging in clinical trials and accelerate the path to regulatory success for novel therapies

How the DYNAMIKA Platform Works and Its Key Features for Clinical Trial Imaging
DYNAMIKA is Image Analysis Group’s award-winning, cloud-based platform designed to streamline and optimize imaging in clinical trials. It serves as a central hub for managing, analyzing, and reviewing imaging data, supporting trials from Phase I to IV across a range of therapeutic areas.

How DYNAMIKA Works:

Centralized Data Management:
DYNAMIKA integrates imaging data from multiple global sites into a single, secure, and manageable database. This enables real-time access and oversight for all trial stakeholders, including sponsors, project managers, and site staff.

Automated Workflows:
The platform automates key imaging processes such as data anonymization, quality control, and audit trails. This reduces manual workload, minimizes site burden, and ensures data security and regulatory compliance (21 CFR Part 11, ISO 13485, SOC II Type I).

AI-Driven Analytics:
DYNAMIKA incorporates advanced AI and machine learning tools to enhance image analysis, power quantitative endpoints, and enable earlier, more sensitive detection of treatment effects. This supports faster, data-driven decision-making and helps sponsors identify efficacy signals sooner.

Central Reads and Quality Control:
The platform enables centralized imaging quality control and radiological review, promoting consistency, accuracy, and reproducibility across global trials.

User-Friendly Interface:
DYNAMIKA’s intuitive design simplifies imaging workflows, making it easy for sites to upload, process, and manage imaging data, and for sponsors to monitor trial progress and performance.

Key Features for Clinical Trial Imaging:

Feature Description
Cloud-Based, Global Access Secure, real-time access for all stakeholders, supporting multi-center international trials
Automated Anonymization Built-in tools to redact personally identifiable information and ensure data privacy
Centralized Quality Control Automated and manual QC processes for consistent, high-quality imaging data
AI-Powered Analytics Embedded AI/ML tools for advanced image analysis and sensitive endpoint development
Regulatory Compliance Developed to meet FDA (21 CFR Part 11), ISO 13485, and SOC II Type I standards
Streamlined Workflows Automation of data ingestion, QC, and audit trails to reduce site and sponsor workload
Central Reads Facilitates blinded, centralized radiological review for unbiased efficacy and safety assessment
Real-Time Trial Oversight Instant visibility into trial status, data quality, and site performance
Data Interoperability Seamless integration and consolidation of imaging and operational data
Award-Winning Innovation Recognized as a 2024 Pharmaceutical Technology Excellence Award winner for driving industry change
Impact and Value:

Accelerates trial timelines by reducing manual processes and enabling earlier interim analyses.

Improves data quality and regulatory readiness through standardized, validated workflows.

Enhances operational efficiency for both sites and sponsors, reducing costs and resource requirements.

Supports complex, global trials in oncology, neurology, rheumatology, and beyond with proven reliability.

DYNAMIKA is trusted by leading biotech and pharma companies to deliver high-quality, reproducible imaging data and actionable insights—empowering confident, data-driven decisions throughout the clinical trial lifecycle

Image Analysis Group (IAG) is at the forefront of integrating artificial intelligence (AI) and advanced analytics into clinical trial imaging, transforming how image review and endpoint assessment are performed for biotech and pharmaceutical sponsors.

Key Approaches and Capabilities:

AI-Powered Endpoints:
IAG utilizes advanced AI algorithms to analyze vast amounts of imaging data, enhancing both safety assessments and efficacy evaluations. These AI-driven endpoints accelerate the detection of treatment effects and improve the overall reliability of trial outcomes.

Automated and Quantitative Analysis:
Through partnerships and proprietary technologies, such as the DYNAMIKA platform, IAG automates data analysis and enables the extraction of biologically interpretable imaging biomarkers. This approach streamlines the identification of early treatment responses, optimizes patient selection, and supports forecasting of therapeutic outcomes with greater accuracy.

Radiomics and Pathomics Integration:
IAG combines radiomics (quantitative features from medical images) and pathomics (features from pathology images) with AI to uncover predictive insights that traditional methods may miss. This synergy allows for more nuanced and personalized assessments, particularly in oncology and complex indications like glioblastoma.

Early and Sensitive Detection:
By applying AI and quantitative imaging, IAG can identify subtle, early changes in disease progression or treatment response that are often undetectable by conventional imaging review. This is especially valuable in challenging indications where distinguishing true progression from pseudo-progression is critical.

Centralized, Blinded Reads:
IAG’s DYNAMIKA platform supports blinded, centralized image review, powered by AI-driven quality control and workflow automation. This ensures consistency, reduces variability, and enhances the reproducibility of imaging endpoints across global multi-site trials.

Regulatory-Grade Compliance:
All AI-powered analytics and image review processes are conducted within a framework that meets stringent regulatory standards (e.g., 21 CFR Part 11, ISO 13485), ensuring data integrity and regulatory acceptance.

Impact for Sponsors:

Accelerated Trial Timelines:
Automated analysis and early detection capabilities help sponsors reach interim and final endpoints faster, reducing trial duration and investment risk.

Improved Data Quality and Consistency:
AI minimizes human variability and enhances the accuracy of imaging-derived endpoints, leading to cleaner, more reliable data for regulatory submissions.

Enhanced Decision-Making:
Real-time analytics and predictive biomarkers enable sponsors to make informed, data-driven decisions throughout the clinical development process

By combining industry-leading certifications (SOC II, BSI, ISO 13485, 21 CFR Part 11) with advanced technology safeguards, IAG delivers a secure, compliant, and reliable environment for clinical trial imaging. These measures ensure that sponsors’ data is protected, regulatory obligations are met, and trial results are trustworthy—making IAG a dependable partner for global clinical development.

Image Analysis Group (IAG) prioritizes the highest standards of data integrity, security, and regulatory compliance in all aspects of clinical trial imaging. The DYNAMIKA platform, IAG’s award-winning cloud-based solution, is designed and operated to meet rigorous industry standards and certifications.

Key Measures and Certifications:

SOC II Type I Compliance:
DYNAMIKA has achieved SOC II Type I compliance, which demonstrates that the platform adheres to stringent security standards for protecting client and patient data. SOC II certification is recognized globally as a benchmark for operational security, risk management, and trust in handling sensitive information.

British Standards Institute (BSI) Certification:
The platform has been certified by the British Standards Institute (BSI) through a surveillance audit, further validating its robust quality management and security controls.

ISO 13485 and 21 CFR Part 11 Compliance:
DYNAMIKA is developed in line with ISO 13485, the internationally recognized standard for quality management systems in medical device design and manufacturing, and 21 CFR Part 11, the FDA’s regulation for electronic records and signatures. This ensures that all imaging data is managed, stored, and processed according to the strictest regulatory requirements.

Technology and Operational Safeguards:

Automated Data Anonymization:
The platform incorporates tools to automatically redact personally identifiable information, ensuring patient privacy and compliance with data protection laws.

Centralized Quality Control and Audit Trails:
DYNAMIKA automates quality control checks and maintains comprehensive audit trails, guaranteeing data integrity and traceability throughout the trial lifecycle.

Secure Cloud Infrastructure:
All imaging data is stored and managed in a secure, cloud-based environment with real-time access controls, supporting both global collaboration and robust data protection.

Consistent Regulatory Oversight:
Regular audits and surveillance by recognized bodies (such as BSI) ensure ongoing compliance and continuous improvement in security protocols

With operational teams, offices, and partnerships spanning the UK, EU, USA, India, China, Australia, and beyond, IAG offers comprehensive, reliable support for imaging clinical trials on a global scale. This extensive reach ensures that sponsors can confidently execute multi-center trials, access diverse patient populations, and benefit from world-class project management—wherever their research takes them.

Image Analysis Group (IAG) operates as a truly global imaging clinical research organization, supporting clinical trials for biotech and pharmaceutical clients across multiple continents and regions.

Key Regions of Operation:

United Kingdom (UK) and Europe (EU):
IAG’s headquarters and core operational teams are based in London, with a strong presence and project management capabilities across the UK and the broader European Union.

United States (USA):
The US is IAG’s fastest-growing market, reflecting rapid adoption of AI-driven imaging in clinical trials. IAG maintains offices and operational teams in the US, supporting a significant portion of its client base and trial activity.

Asia-Pacific:
IAG has established teams in India and partnerships in China and Australia, enabling effective support for trials throughout the Asia-Pacific region.

Africa and Other Regions:
The company’s reach extends to Africa and other regions. This expansive network allows IAG to manage and deliver trials in diverse regulatory and clinical environments.

Operational Highlights:

Global Site Network:
IAG maintains a well-connected network of clinical sites and radiology readers, enabling rapid site setup, efficient data collection, and seamless trial execution across borders.

International Revenue and Impact:
65% of IAG’s revenue comes from outside the UK, with the US as the leading growth region. This demonstrates IAG’s strong international footprint and ability to deliver results for clients worldwide.

Comprehensive Support:
IAG provides end-to-end imaging trial management for Phase I-III studies and real-world evidence projects, leveraging local expertise and global oversight to ensure regulatory compliance and operational excellence

By leveraging a global site and reader network, expert project management, and the award-winning DYNAMIKA platform, IAG ensures rapid site set-up, consistent radiology review, and secure, efficient data collection for clinical trials anywhere in the world. This integrated approach accelerates timelines, enhances data quality, and supports successful trial outcomes for sponsors.

How IAG Manages Site Set-Up, Radiology Reader Networks, and Data Collection Across Multiple Geographies
Image Analysis Group (IAG) delivers seamless global clinical trial execution by combining a robust operational infrastructure, a well-connected network of sites and radiology readers, and its advanced DYNAMIKA platform.

Site Set-Up and Radiology Reader Networks:

IAG maintains a global network of clinical sites and radiology readers, enabling rapid site activation and efficient trial initiation in the USA, EU, UK, China, India, South America, and beyond.

Experienced project managers and operational teams, strategically located across key regions, oversee site feasibility, onboarding, and regulatory compliance, ensuring trials are launched efficiently and in accordance with local requirements.

The radiology reader network is integrated with the DYNAMIKA platform, supporting centralized, blinded reads and ensuring consistency and quality across all imaging assessments.

Data Collection and Management:

IAG’s DYNAMIKA platform is the backbone for global imaging data management, providing a cloud-based, secure hub for image collection, storage, and analysis.

DYNAMIKA automates critical processes, including image anonymization, quality control, and audit trails, minimizing manual workload at sites and ensuring data integrity and regulatory compliance (ISO 13485, 21 CFR Part 11).

The platform supports real-time data ingestion and centralized quality control, allowing project managers and sponsors to monitor trial progress and site performance instantly from anywhere in the world.

AI-driven workflows and digital assistance enhance site performance, streamline radiology reads, and reduce operational costs, while ensuring high reproducibility and data security.

Operational Excellence Across Geographies:

IAG’s global presence—with teams in the UK, EU, USA, India, China, Australia, and additional offices in Singapore, the Netherlands, and Nigeria—ensures comprehensive support for multinational studies and adaptation to diverse regulatory environments.

The company’s integrated approach, combining medical, technological, and operational expertise, guarantees that data collection and trial delivery are efficient, transparent, and tailored to each sponsor’s needs